SurModics (SRDX) Tops Q4 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. USO
2. MRVL
3. SPY
4. NVDA
5. BBIO
6. GOOGL
7. OPCH
8. AMD
9. CHRW
10. SKYD

Go back to SurModics (SRDX) Tops Q4 EPS by 15c

Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance

November 10, 2021 7:30 AM EST

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022.

Summary of Fourth Quarter and Recent Highlights

Revenue of $24.0 million, an increase of 6% year-over-year GAAP EPS of $(0.02), non-GAAP EPS of $(0.10) Successful first patient use Sublime .018 RX PTA Dilatation Catheter

Were extremely pleased to share that the Sublime and Pounce clinical product... More